Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood

Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical and pediatric oncology 1993, Vol.21 (2), p.103-110
Hauptverfasser: Toogood, Ian R. G., Tiedemann, Karin, Stevens, Michael, Smith, Peter J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 110
container_issue 2
container_start_page 103
container_title Medical and pediatric oncology
container_volume 21
creator Toogood, Ian R. G.
Tiedemann, Karin
Stevens, Michael
Smith, Peter J.
description Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only. There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation. Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.
doi_str_mv 10.1002/mpo.2950210205
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mpo_2950210205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MPO2950210205</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</originalsourceid><addsrcrecordid>eNqFkMtPGzEQxi1URAP0yq2SD71u8GO9Xh8pghQUHqqomps160fjso5Xuxto_vu6ShTUE6eZ0XzfPH4InVEypYSw89ilKVOCMEoYEQdoQomqCkXp4gOaEKLqggrOPqLjYfhNcq1kfYSO6pLzSooJMlfeOzOGF4fjuh1DAb_casRm6WIal66HboN96jHYF1gZZzE0NsWwgha3m9gtUwQMK4uvL77iOcetWz-7GAAnn2eE1i5Tsqfo0EM7uE-7eIJ-XF89XX4r5g-zm8uLeWE4Y6KglWtMpYz0THIiSpCiIpQBNdKoUjZNIygXKpegBDVGgGlYXZf5v9JbK_kJmm7nmj4NQ--87voQod9oSvQ_WDrD0m-wsuHz1tCtm-jsXr6jk_tfdn0YDLS-zwjCsJeVopKM0ixTW9lraN3mnaX67vHhvxOKrTcMo_uz90L_rCvJpdA_72c5W3yvH2e3esH_ArUFkcM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Toogood, Ian R. G. ; Tiedemann, Karin ; Stevens, Michael ; Smith, Peter J.</creator><creatorcontrib>Toogood, Ian R. G. ; Tiedemann, Karin ; Stevens, Michael ; Smith, Peter J.</creatorcontrib><description>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only. There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation. Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/mpo.2950210205</identifier><identifier>PMID: 8433675</identifier><identifier>CODEN: MPONDB</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject><![CDATA[Abdominal Neoplasms - drug therapy ; Adolescent ; advanced non-Hodgkin′s lymphoma ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asparaginase - administration & dosage ; Asparaginase - adverse effects ; B-cell leukaemia ; Biological and medical sciences ; Burkitt Lymphoma - drug therapy ; Chemotherapy ; Child ; Child, Preschool ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Cytarabine - administration & dosage ; Cytarabine - adverse effects ; diffuse undifferentiated histology ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Female ; Humans ; Infant ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Medical sciences ; Methotrexate - administration & dosage ; Methotrexate - adverse effects ; Neoplasm Recurrence, Local ; Neoplasms, Multiple Primary - drug therapy ; Pharmacology. Drug treatments ; Prednisolone - administration & dosage ; Prednisolone - adverse effects ; Remission Induction ; Retrospective Studies ; Survival Rate ; Teniposide - administration & dosage ; Teniposide - adverse effects ; treatment ; Vincristine - administration & dosage ; Vincristine - adverse effects]]></subject><ispartof>Medical and pediatric oncology, 1993, Vol.21 (2), p.103-110</ispartof><rights>Copyright © 1993 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1993 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</citedby><cites>FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmpo.2950210205$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmpo.2950210205$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4567211$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8433675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toogood, Ian R. G.</creatorcontrib><creatorcontrib>Tiedemann, Karin</creatorcontrib><creatorcontrib>Stevens, Michael</creatorcontrib><creatorcontrib>Smith, Peter J.</creatorcontrib><title>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only. There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation. Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.</description><subject>Abdominal Neoplasms - drug therapy</subject><subject>Adolescent</subject><subject>advanced non-Hodgkin′s lymphoma</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asparaginase - administration &amp; dosage</subject><subject>Asparaginase - adverse effects</subject><subject>B-cell leukaemia</subject><subject>Biological and medical sciences</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - administration &amp; dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Cytarabine - administration &amp; dosage</subject><subject>Cytarabine - adverse effects</subject><subject>diffuse undifferentiated histology</subject><subject>Doxorubicin - administration &amp; dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - administration &amp; dosage</subject><subject>Methotrexate - adverse effects</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasms, Multiple Primary - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisolone - administration &amp; dosage</subject><subject>Prednisolone - adverse effects</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Teniposide - administration &amp; dosage</subject><subject>Teniposide - adverse effects</subject><subject>treatment</subject><subject>Vincristine - administration &amp; dosage</subject><subject>Vincristine - adverse effects</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtPGzEQxi1URAP0yq2SD71u8GO9Xh8pghQUHqqomps160fjso5Xuxto_vu6ShTUE6eZ0XzfPH4InVEypYSw89ilKVOCMEoYEQdoQomqCkXp4gOaEKLqggrOPqLjYfhNcq1kfYSO6pLzSooJMlfeOzOGF4fjuh1DAb_casRm6WIal66HboN96jHYF1gZZzE0NsWwgha3m9gtUwQMK4uvL77iOcetWz-7GAAnn2eE1i5Tsqfo0EM7uE-7eIJ-XF89XX4r5g-zm8uLeWE4Y6KglWtMpYz0THIiSpCiIpQBNdKoUjZNIygXKpegBDVGgGlYXZf5v9JbK_kJmm7nmj4NQ--87voQod9oSvQ_WDrD0m-wsuHz1tCtm-jsXr6jk_tfdn0YDLS-zwjCsJeVopKM0ixTW9lraN3mnaX67vHhvxOKrTcMo_uz90L_rCvJpdA_72c5W3yvH2e3esH_ArUFkcM</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>Toogood, Ian R. G.</creator><creator>Tiedemann, Karin</creator><creator>Stevens, Michael</creator><creator>Smith, Peter J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1993</creationdate><title>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</title><author>Toogood, Ian R. G. ; Tiedemann, Karin ; Stevens, Michael ; Smith, Peter J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Abdominal Neoplasms - drug therapy</topic><topic>Adolescent</topic><topic>advanced non-Hodgkin′s lymphoma</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asparaginase - administration &amp; dosage</topic><topic>Asparaginase - adverse effects</topic><topic>B-cell leukaemia</topic><topic>Biological and medical sciences</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - administration &amp; dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Cytarabine - administration &amp; dosage</topic><topic>Cytarabine - adverse effects</topic><topic>diffuse undifferentiated histology</topic><topic>Doxorubicin - administration &amp; dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - administration &amp; dosage</topic><topic>Methotrexate - adverse effects</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasms, Multiple Primary - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisolone - administration &amp; dosage</topic><topic>Prednisolone - adverse effects</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Teniposide - administration &amp; dosage</topic><topic>Teniposide - adverse effects</topic><topic>treatment</topic><topic>Vincristine - administration &amp; dosage</topic><topic>Vincristine - adverse effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Toogood, Ian R. G.</creatorcontrib><creatorcontrib>Tiedemann, Karin</creatorcontrib><creatorcontrib>Stevens, Michael</creatorcontrib><creatorcontrib>Smith, Peter J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toogood, Ian R. G.</au><au>Tiedemann, Karin</au><au>Stevens, Michael</au><au>Smith, Peter J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>1993</date><risdate>1993</risdate><volume>21</volume><issue>2</issue><spage>103</spage><epage>110</epage><pages>103-110</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><coden>MPONDB</coden><abstract>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only. There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation. Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8433675</pmid><doi>10.1002/mpo.2950210205</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0098-1532
ispartof Medical and pediatric oncology, 1993, Vol.21 (2), p.103-110
issn 0098-1532
1096-911X
language eng
recordid cdi_crossref_primary_10_1002_mpo_2950210205
source MEDLINE; Access via Wiley Online Library
subjects Abdominal Neoplasms - drug therapy
Adolescent
advanced non-Hodgkin′s lymphoma
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asparaginase - administration & dosage
Asparaginase - adverse effects
B-cell leukaemia
Biological and medical sciences
Burkitt Lymphoma - drug therapy
Chemotherapy
Child
Child, Preschool
Cyclophosphamide - administration & dosage
Cyclophosphamide - adverse effects
Cytarabine - administration & dosage
Cytarabine - adverse effects
diffuse undifferentiated histology
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Female
Humans
Infant
Lymphoma, Non-Hodgkin - drug therapy
Male
Medical sciences
Methotrexate - administration & dosage
Methotrexate - adverse effects
Neoplasm Recurrence, Local
Neoplasms, Multiple Primary - drug therapy
Pharmacology. Drug treatments
Prednisolone - administration & dosage
Prednisolone - adverse effects
Remission Induction
Retrospective Studies
Survival Rate
Teniposide - administration & dosage
Teniposide - adverse effects
treatment
Vincristine - administration & dosage
Vincristine - adverse effects
title Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T11%3A38%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20multi-agent%20chemotherapy%20for%20advanced%20abdominal%20lymphoma%20and%20FAB%20L3%20leukemia%20of%20childhood&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=Toogood,%20Ian%20R.%20G.&rft.date=1993&rft.volume=21&rft.issue=2&rft.spage=103&rft.epage=110&rft.pages=103-110&rft.issn=0098-1532&rft.eissn=1096-911X&rft.coden=MPONDB&rft_id=info:doi/10.1002/mpo.2950210205&rft_dat=%3Cwiley_cross%3EMPO2950210205%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8433675&rfr_iscdi=true